Shares of Skyline Medical Inc (NASDAQ:SKLN) ended Thursday session in red amid volatile trading. The shares closed down -0.014 points or -9.27% at $0.140 with 5.69 million shares getting traded. Post opening the session at $0.15, the shares hit an intraday low of $0.12 and an intraday high of $0.15 and the price vacillated in this range throughout the day. The company has a market cap of $10.87 million and the numbers of outstanding shares have been calculated to be 81.80 million shares.
Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods — which require hand carrying and emptying filled fluid canisters — present an exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers, 2) improve compliance with OSHA and other regulatory agency safety guidelines, 3) improve efficiency in the operating room, and radiology and endoscopy departments — leading to greater profitability, and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United States.
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ended Thursday session in red amid volatile trading. The shares closed down -0.05 points or -0.88% at $5.62 with 1.12 million shares getting traded. Post opening the session at $5.61, the shares hit an intraday low of $5.53 and an intraday high of $5.70 and the price vacillated in this range throughout the day. The company has a market cap of $744.27 million and the numbers of outstanding shares have been calculated to be 131.73 million shares.
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexons synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 that is used with the oral activator veledimex and evaluated for the treatment of metastatic melanoma and unresectable recurrent or metastatic breast cancer.